文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

Romiplostim治疗难治性再生障碍性贫血的剂量探索与长期治疗II期试验

Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
PubMed 文献 · Lancet Haematol · 2019-08-29

这项在韩国两个中心开展的开放标签II期试验,纳入35例既往接受免疫抑制治疗的再生障碍性贫血患者,随机分配至1、3、6或10 μg/kg romiplostim皮下注射8周,随后扩展治疗至3年。第9周时33例可评估患者中10例(30%)达血小板反应,10 μg/kg组为7/10(70%)。长期治疗中10例(30%)维持血小板反应至2年和3年。治疗相关不良事件发生率为9%,无克隆演化。

要点

  • 10 μg/kg每周一次romiplostim在难治性再生障碍性贫血中显示活性,第9周血小板反应率70%。
  • 长期治疗中30%患者维持血小板反应至2年和3年,部分伴红系和中性粒细胞反应。
  • 治疗相关不良事件少(9%),无克隆演化,安全性良好。

核心结论

  • Romiplostim在难治性再生障碍性贫血中似乎具有活性且安全性良好。
  • 10 μg/kg每周一次可作为未来研究的推荐起始剂量。

研究设计与样本

  • 开放标签、II期研究,包括随机平行剂量探索部分和长期扩展治疗部分,在韩国首尔两个临床中心进行。
  • 纳入35例年龄≥19岁、确诊再生障碍性贫血、血小板计数≤30×10^9/L、ECOG体能状态评分≤2、既往接受过至少一疗程抗胸腺细胞球蛋白联合环孢素的免疫抑制治疗的患者。
  • 剂量探索部分随机分配至1、3、6或10 μg/kg固定剂量队列,每周皮下注射一次,共8周;扩展部分每4周单步滴定(1、3、6、10、13、16、20 μg/kg每周一次)至1年,有反应者继续滴定额外2年。
  • 主要终点为第9周(剂量探索部分完成后)达到血小板反应的患者比例。

主要发现

  • 第9周33例可评估患者中10例(30%)达血小板反应,其中10 μg/kg队列7/10(70%),6 μg/kg队列3/9(33%),3 μg/kg和1 μg/kg队列均无反应。
  • 扩展研究中33例可评估患者中18例(55%)在第46-53周有血小板反应并符合继续治疗资格;10例(30%)在2年和3年维持血小板反应,其中9例有红系反应、5例有中性粒细胞反应。
  • 治疗相关不良事件发生于3/35(9%)患者,包括1-2级肌痛、疲劳和头晕;17/35(49%)发生≥3级不良事件;7/35(20%)发生严重不良事件;1例死于脓毒症;均与治疗无关;无患者出现克隆演化。

关键数值与推荐

  • 第9周血小板反应率:总体30%(10/33),10 μg/kg组70%(7/10),6 μg/kg组33%(3/9),3 μg/kg和1 μg/kg组均为0%。
  • 第46-53周血小板反应率55%(18/33);2年和3年维持血小板反应率30%(10/33)。
  • 治疗相关不良事件发生率9%(3/35);≥3级不良事件发生率49%(17/35);严重不良事件发生率20%(7/35)。

临床怎么用

  • 对于既往免疫抑制治疗失败的难治性再生障碍性贫血患者,romiplostim可能作为一种治疗选择。
  • 10 μg/kg每周一次可作为未来临床研究的推荐起始剂量。
  • 治疗期间需监测血小板反应及不良事件,长期治疗中部分患者可获得红系和中性粒细胞反应。

局限性

  • 样本量小(35例),为开放标签研究,无安慰剂对照。
  • 研究仅在韩国两个中心进行,结果外推需谨慎。
  • 长期扩展部分数据有限,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aplastic anaemia is a rare, life-threatening condition, characterised by pancytopenia with hypocellular bone marrow. Haematopoietic stem cells and most progenitor cells express thrombopoietin receptor (c-MPL). Romiplostim is a peptibody with c-MPL agonist activity that stimulates endogenous thrombopoietin production and leads to promoting the proliferation and differentiation of megakaryocytes in the bone marrow. In this phase 2 trial we aimed to assess the activity and safety of romiplostim in patients with aplastic anaemia who were previously treated with immunosuppressive therapy. METHODS: We did an open-label, phase 2 study including a randomised, parallel, dose-finding part followed by an extension part to evaluate long-term treatment at two clinical centres in Seoul, South Korea. Eligible patients were aged 19 years or older, and had aplastic anaemia confirmed by bone marrow and cytogenetic studies and thrombocytopenia (platelet count ≤30 × 109/L), an Eastern Cooperative Oncology Group performance status score of 2 or lower, and were previously treated with immunosuppressive therapy, including at least one course of antithymocyte globulin plus cyclosporin. In the dose-finding part, patients were randomly assigned to fixed dose cohorts (1, 3, 6, or 10 μg/kg) of subcutaneous romiplostim once weekly for 8 weeks, according to a static allocation procedure after stratification by platelet count. In the extension part of the study, patients continued romiplostim titrated every 4 weeks in single steps (1, 3, 6, 10, 13, 16, and 20 μg/kg once weekly), depending on platelet response and safety up to 1 year (weeks 9-52). Patients who had a platelet response during weeks 46-53 continued dose titration in single steps (3, 6, 10, 13, 16, and 20 μg/kg once weekly) for an additional 2 years (weeks 53-156). The primary endpoint was the proportion of patients achieving a platelet response at week 9 (after completion of the dose-finding part). Activity was assessed per-protocol in all patients evaluable for response at week 9 and safety was assessed in all patients who received at least one dose of romiplostim. This trial is registered with ClinicalTrials.gov, NCT02094417. FINDINGS: Between April 14 and Nov 24, 2014, 35 patients were enrolled and randomly assigned to one of four dose cohorts: romiplostim 1 μg/kg (n=7), 3 μg/kg (n=9), 6 μg/kg (n=9), and 10 μg/kg (n=10). Data cutoff for this final analysis was on April 14, 2018. The median duration of treatment for all patients was 53 weeks (IQR 35-155). Ten (30%) of 33 evaluable patients achieved a platelet response at week 9, including seven (70%) of ten patients in the 10 μg/kg cohort, three (33%) of nine patients in the 6 μg/kg cohort, and no patients in both the 3 μg/kg and 1 μg/kg cohorts. During the extension study, 18 (55%) of 33 evaluable patients had a platelet response during weeks 46-53 and were eligible for continued treatment. Ten (30%) patients maintained a platelet response at 2 and 3 years, of whom nine had an erythroid response and five a neutrophil response, and completed protocol treatment. Treatment-related adverse events occurred in three (9%) of 35 patients, including grade 1 or 2 myalgia, fatigue, and dizziness. 17 (49%) of 35 patients had adverse events of grade 3 or higher; seven (20%) had serious adverse events (one event of febrile neutropenia, cataract, retinal detachment, macular fibrosis, inguinal hernia, appendicitis, cellulitis, tendon injury, and transfusion reaction); and one patient died from sepsis during treatment; none of these events were related to treatment. No patients developed clonal evolution. INTERPRETATION: Romiplostim seems to be active and has a favourable safety profile in patients with refractory aplastic anaemia. 10 μg/kg once weekly might be used as a recommended starting dose in future studies. These findings warrant further investigation. FUNDING: Kyowa Hakko Kirin Korea.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019. PMID: 31474546. doi:10.1016/S2352-3026(19)30153-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。